Zydus receives tentative approval from USFDA for Enzalutamide Tablets, 40 mg and 80 mg

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as "Zydus") has received tentative approval from the United States Food and Drug Administration (USFDA) to manufacture Enzalutamide Tablets, 40 mg and 80 mg (USRLD: Xtandi® Tablets, 40 mg, 80 mg).

Enzalutamide tablets are androgen receptor inhibitors indicated for the treatment of patients with castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. Enzalutamide Tablets will be produced at the Group's manufacturing site at SEZ, Ahmedabad.

Enzalutamide tablets, 40 mg and 80 mg had annual sales of USD 1417.2 mn in the United States (IQVIA MAT July 2024).

The group now has 400 approvals and has so far filed over 465* ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 1080.60 as compared to the previous close of Rs. 1068.35. The total number of shares traded during the day was 13178 in over 1498 trades.

The stock hit an intraday high of Rs. 1083.70 and intraday low of 1063.00. The net turnover during the day was Rs. 14141946.00.

(*as of 30th June 2024)

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 Pharmaceuticals USFDA TentativeApproval EnzalutamideTablets